Targeting the tumor microenvironment with mesenchymal stem cells based delivery approach for efficient delivery of anticancer agents: An updated review
- PMID: 39746456
- DOI: 10.1016/j.bcp.2024.116725
Targeting the tumor microenvironment with mesenchymal stem cells based delivery approach for efficient delivery of anticancer agents: An updated review
Abstract
Drug delivery to cancer cells continues to present a major therapeutic challenge. Mesenchymal stem cells (MSCs) possess an intrinsic ability to migrate specifically to tumor tissues, making them promising candidates for targeted drug delivery. Evidence from preclinical studies indicates that MSCs loaded with therapeutic anti-cancer agents exhibit considerable anti-tumor activity. Moreover, several clinical trials are currently evaluating their effectiveness in cancer patients. The integration of MSCs with synthetic nanoparticles (NPs) enhances their therapeutic potential, particularly through the use of cell membrane-coated NPs, which represent a significant advancement in the field. This review systematically investigates the tumor microenvironment, the sources of MSCs, the tumor homing mechanisms, and the methods of loading and releasing anticancer drugs from MSCs. Furthermore, cutting-edge strategies to improve the efficacy of MSCs based drug delivery systems (DDS) including the innovative use of MSC membrane coated nanoparticles have been discussed. The study concludes with an overview of the therapeutic use of MSCs as drug carriers, including a detailed analysis of the mechanisms by which MSCs deliver therapeutics to cancer cells, enabling targeted drug delivery. It aims to elucidate the current state of this approach, identify key areas for development, and outline potential future directions for advancing MSCs based cancer therapies.
Keywords: Cancer; Mesenchymal Stem Cells; Targeted Drug delivery; Tumor Microenvironment.
Copyright © 2024 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Nano-Engineered Mesenchymal Stem Cells Increase Therapeutic Efficacy of Anticancer Drug Through True Active Tumor Targeting.Mol Cancer Ther. 2018 Jun;17(6):1196-1206. doi: 10.1158/1535-7163.MCT-17-0682. Epub 2018 Mar 28. Mol Cancer Ther. 2018. PMID: 29592881 Free PMC article.
-
Mesenchymal stem cells: a potential targeted-delivery vehicle for anti-cancer drug, loaded nanoparticles.Nanomedicine. 2013 Feb;9(2):174-84. doi: 10.1016/j.nano.2012.06.003. Epub 2012 Jul 5. Nanomedicine. 2013. PMID: 22772046 Review.
-
Perspectives in Engineered Mesenchymal Stem/Stromal Cells Based Anti- Cancer Drug Delivery Systems.Recent Pat Anticancer Drug Discov. 2016;11(1):98-111. doi: 10.2174/1574892811666151111142721. Recent Pat Anticancer Drug Discov. 2016. PMID: 26554397 Review.
-
Navigating the tumor microenvironment: mesenchymal stem cell-mediated delivery of anticancer agents.J Drug Target. 2024 Jul;32(6):624-634. doi: 10.1080/1061186X.2024.2347356. Epub 2024 May 6. J Drug Target. 2024. PMID: 38652480 Review.
-
[Application of mesenchymal stem cells in antineoplastic drugs delivery for tumor-targeted therapy].Zhejiang Da Xue Xue Bao Yi Xue Ban. 2018 May 25;47(5):525-533. doi: 10.3785/j.issn.1008-9292.2018.10.13. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2018. PMID: 30693696 Free PMC article. Review. Chinese.
Cited by
-
Benign non-immune cells in tumor microenvironment.Front Immunol. 2025 Apr 3;16:1561577. doi: 10.3389/fimmu.2025.1561577. eCollection 2025. Front Immunol. 2025. PMID: 40248695 Free PMC article. Review.
-
Potential of Using New Indole- and Benzimidazo[1,2-C]quinazolines in Anticancer Therapy Based on Mesenchymal Stem Cells.Cancer Manag Res. 2025 Jun 11;17:1087-1097. doi: 10.2147/CMAR.S516593. eCollection 2025. Cancer Manag Res. 2025. PMID: 40524709 Free PMC article.
-
Cryo-trojan mesenchymal stem cells as non-living tumor-homing supercarriers for enhanced drug delivery and immune activation in prostate cancer.Mater Today Bio. 2025 Mar 12;32:101650. doi: 10.1016/j.mtbio.2025.101650. eCollection 2025 Jun. Mater Today Bio. 2025. PMID: 40151804 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical